These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32639951)

  • 1. An individualized transcriptional signature to predict the epithelial-mesenchymal transition based on relative expression ordering.
    Chen T; Zhao Z; Chen B; Wang Y; Yang F; Wang C; Dong Q; Liu Y; Liang H; Zhao W; Qi L; Xu Y; Gu Y
    Aging (Albany NY); 2020 Jul; 12(13):13172-13186. PubMed ID: 32639951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.
    Tan TZ; Miow QH; Miki Y; Noda T; Mori S; Huang RY; Thiery JP
    EMBO Mol Med; 2014 Oct; 6(10):1279-93. PubMed ID: 25214461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma.
    Jung AR; Jung CH; Noh JK; Lee YC; Eun YG
    Sci Rep; 2020 Feb; 10(1):3652. PubMed ID: 32107458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer.
    Liang J; Liu Z; Zou Z; Tang Y; Zhou C; Yang J; Wei X; Lu Y
    Sci Rep; 2018 Apr; 8(1):6570. PubMed ID: 29700419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
    Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
    Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    Wang D; Haley JD; Thompson P
    BMC Cancer; 2017 Dec; 17(1):830. PubMed ID: 29212455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
    Lutgendorf SK; Penedo F; Goodheart MJ; Dahmoush L; Arevalo JMG; Thaker PH; Slavich GM; Sood AK; Cole SW
    Cancer; 2020 Oct; 126(19):4407-4413. PubMed ID: 32691853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Yi BR; Kim TH; Kim YS; Choi KC
    Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
    Huang RY; Kuay KT; Tan TZ; Asad M; Tang HM; Ng AH; Ye J; Chung VY; Thiery JP
    Oncotarget; 2015 Sep; 6(26):22098-113. PubMed ID: 26061747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFβ-induced epithelial-to-mesenchymal transition.
    Du L; Yamamoto S; Burnette BL; Huang D; Gao K; Jamshidi N; Kuo MD
    Cancer Med; 2016 Aug; 5(8):1962-72. PubMed ID: 27318801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
    Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
    BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.
    Yiqi Z; Ziyun L; Qin F; Xingli W; Liyu Y
    Technol Cancer Res Treat; 2020; 19():1533033820980769. PubMed ID: 33308057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.